A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate

• Published in: Journal of rheumatology Vol. 42; no. 6; p. 912
• Main Authors: Pavelka, Karel, Chon, Yun, Newmark, Richard, Lin, Shao-Lee, Baumgartner, Scott, Erondu, Ngozi
• Format: Journal Article
• Language: English
• Published: Canada 01.06.2015
• Subjects: Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Methotrexate - therapeutic use; Middle Aged; Multivariate Analysis; Pain Measurement; Prospective Studies; Retreatment - methods; Risk Assessment; Severity of Illness Index; Treatment Failure; Treatment Outcome; INTERLEUKIN 17; BRODALUMAB; RHEUMATOID ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; PHASE 2
• ISSN: 0315-162X
• DOI: 10.3899/jrheum.141271

To evaluate the efficacy and safety of brodalumab, a human monoclonal antibody inhibitor of the interleukin 17 receptor, in subjects with rheumatoid arthritis (RA). Patients (n = 252) with inadequate response to methotrexate (MTX) were randomized to receive subcutaneous injections of brodalumab (70 mg, 140 mg, or 210 mg) or placebo. The primary endpoint was the American College of Rheumatology 50% response (ACR50) at Week 12. Demographics and baseline characteristics were generally balanced among treatment groups. At Week 12, ACR50 occurred in 16% (70 mg), 16% (140 mg), 10% (210 mg), and 13% (placebo; all nonsignificant vs placebo) of subjects. No significant treatment effects were observed for the secondary endpoints, including ACR20, ACR70, and Disease Activity Score in 28 joints. Incidences of all adverse events (AE), including serious AE (SAE), were similar across treatment groups. A total of 7 subjects reported SAE during the study (2 in the placebo group and 5 in the brodalumab groups), none of which was treatment related. There was 1 death (cardiopulmonary failure) ∼1 week after the last dose in the 140 mg group. Our study failed to find evidence of meaningful clinical efficacy with brodalumab treatment in subjects with RA who had an inadequate response to MTX. These preliminary results do not support further evaluation of brodalumab as a treatment for RA. Clinicaltrials.gov number: NCT00950989.